<?xml version="1.0" encoding="UTF-8"?>
<p>In a recent study, it was demonstrated that SARS-CoV-2 and SARS-CoV share a remarkable 96% sequence identity in their 3CL
 <sup>pro</sup> and RdRp and 83% sequence identity in their PL
 <sup>pro</sup>.
 <sup>
  <xref ref-type="bibr" rid="ref11">11</xref>,
  <xref ref-type="bibr" rid="ref12">12</xref>
 </sup> Therefore, existing SARS-CoV inhibitors may be effective against SARS-CoV-2.
 <sup>
  <xref ref-type="bibr" rid="ref89">89</xref>,
  <xref ref-type="bibr" rid="ref90">90</xref>
 </sup>
 <xref rid="fig3" ref-type="fig">Figure 
  <xref rid="fig3" ref-type="fig">3</xref>
 </xref>represents the candidate antiviral agents for SARS-CoV-2.
</p>
